Human and Rat Mesangial Cell Receptors for Glucose-modified Proteins: Potential Role in Kidney Tissue Remodelling and Diabetic Nephropathy

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1991 Oct 1

PMID 1655949

Citations 44

Authors

E Y Skolnik

Z Yang

Z Makita

S Radoff

M Kirstein

H Vlassara

Affiliations

Soon will be listed here.

Abstract

Advanced glycosylation endproducts (AGEs) are derived from the nonenzymatic addition of glucose to proteins. AGEs have been found to accumulate on tissue proteins in patients with diabetes, and their accumulation is thought to play a role in the development of diabetic complications. The finding that macrophages and endothelial cells contain AGE-specific receptors led us to examine whether mesangial cells (MCs) also possess a mechanism for recognizing and processing AGEs. Membrane extracts isolated from rat and human MCs were found to bind AGE-bovine serum albumin (BSA) in a saturable fashion, with a binding affinity of 2.0 +/- 0.4 x 10(6) M-1 (500 nM). The binding was specific for the AGE adduct, since AGE-modified collagen I and ribonuclease both competitively inhibited 125I-AGE-BSA binding to MC membranes, while the unmodified proteins did not compete. Binding of AGE proteins was followed by slow internalization and degradation of the ligand. Ligand blotting of MC membrane extracts demonstrated three distinct AGE-binding membrane proteins of 50, 40, and 30 kD. Growth of MCs on various AGE-modified matrix proteins resulted in alterations in MC function, as demonstrated by enhanced production of fibronectin and decreased proliferation. These results point to the potential role that the interaction of AGE-modified proteins with MCs may play in vivo in promoting diabetic kidney disease.

Citing Articles

Immune Modulation by Myeloid-Derived Suppressor Cells in Diabetic Kidney Disease.

Hsieh C, Chang C, Hsu Y, Lin C Int J Mol Sci. 2022; 23(21).

PMID: 36362050 PMC: 9655277. DOI: 10.3390/ijms232113263.

Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells.

Chang J, Liang Y, Hsu C, Chen C, Chen P, Yang Y BMC Pharmacol Toxicol. 2017; 18(1):67.

PMID: 29065926 PMC: 5655807. DOI: 10.1186/s40360-017-0172-3.

Constructing the toolbox: Patient-specific genetic factors of altered fracture healing.

Drissi H, Paglia D, Alaee F, Yoshida R Genes Dis. 2015; 1(2):140-148.

PMID: 25558470 PMC: 4280851. DOI: 10.1016/j.gendis.2014.07.006.

Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects.

Zhang Q, Monroe M, Schepmoes A, Clauss T, Gritsenko M, Meng D J Proteome Res. 2011; 10(7):3076-88.

PMID: 21612289 PMC: 3128674. DOI: 10.1021/pr200040j.

AGE restriction in diabetes mellitus: a paradigm shift.

Vlassara H, Striker G Nat Rev Endocrinol. 2011; 7(9):526-39.

PMID: 21610689 PMC: 3708644. DOI: 10.1038/nrendo.2011.74.

References

Monnier V, Kohn R, Cerami A . Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A. 1984; 81(2):583-7. PMC: 344723. DOI: 10.1073/pnas.81.2.583. View

Thomsen O, Andersen A, Christiansen J, Deckert T . Renal changes in long-term type 1 (insulin-dependent) diabetic patients with and without clinical nephropathy: a light microscopic, morphometric study of autopsy material. Diabetologia. 1984; 26(5):361-5. DOI: 10.1007/BF00266037. View

Edwards C, OBrien Jr W . Modified assay for determination of hydroxyproline in a tissue hydrolyzate. Clin Chim Acta. 1980; 104(2):161-7. DOI: 10.1016/0009-8981(80)90192-8. View

Schneider W, Basu S, McPhaul M, Goldstein J, Brown M . Solubilization of the low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1979; 76(11):5577-81. PMC: 411692. DOI: 10.1073/pnas.76.11.5577. View

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

Crowley S, Brownlee M, Edelstein D, Satriano J, Mori T, Singhal P . Effects of nonenzymatic glycosylation of mesangial matrix on proliferation of mesangial cells. Diabetes. 1991; 40(5):540-7. DOI: 10.2337/diab.40.5.540. View

Radoff S, Cerami A, Vlassara H . Isolation of surface binding protein specific for advanced glycosylation end products from mouse macrophage-derived cell line RAW 264.7. Diabetes. 1990; 39(12):1510-8. DOI: 10.2337/diab.39.12.1510. View

Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H . Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A. 1990; 87(22):9010-4. PMC: 55090. DOI: 10.1073/pnas.87.22.9010. View

Werber H, Emancipator S, Tykocinski M, Sedor J . The interleukin 1 gene is expressed by rat glomerular mesangial cells and is augmented in immune complex glomerulonephritis. J Immunol. 1987; 138(10):3207-12. View

10.

Vlassara H, Brownlee M, Cerami A . High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci U S A. 1985; 82(17):5588-92. PMC: 390596. DOI: 10.1073/pnas.82.17.5588. View

11.

Simonson M, Culp L, Dunn M . Rat mesangial cell-matrix interactions in culture. Exp Cell Res. 1989; 184(2):484-98. DOI: 10.1016/0014-4827(89)90346-7. View

12.

Vlassara H, Moldawer L, Chan B . Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. J Clin Invest. 1989; 84(6):1813-20. PMC: 304059. DOI: 10.1172/JCI114366. View

13.

Esposito C, Gerlach H, Brett J, Stern D, Vlassara H . Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med. 1989; 170(4):1387-407. PMC: 2189465. DOI: 10.1084/jem.170.4.1387. View

14.

MacKay K, Striker L, Stauffer J, Doi T, Agodoa L, Striker G . Transforming growth factor-beta. Murine glomerular receptors and responses of isolated glomerular cells. J Clin Invest. 1989; 83(4):1160-7. PMC: 303802. DOI: 10.1172/JCI113996. View

15.

Wasserman J, Santiago A, Rifici V, Holthofer H, Scharschmidt L, Epstein M . Interactions of low density lipoprotein with rat mesangial cells. Kidney Int. 1989; 35(5):1168-74. DOI: 10.1038/ki.1989.106. View

16.

Brownlee M, Cerami A, Vlassara H . Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988; 318(20):1315-21. DOI: 10.1056/NEJM198805193182007. View

17.

Vlassara H, Brownlee M, Manogue K, Dinarello C, Pasagian A . Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science. 1988; 240(4858):1546-8. DOI: 10.1126/science.3259727. View

18.

Kodama T, Reddy P, Kishimoto C, Krieger M . Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1988; 85(23):9238-42. PMC: 282714. DOI: 10.1073/pnas.85.23.9238. View

19.

Schreiner G, UNANUE E . Origin of the rat mesangial phagocyte and its expression of the leukocyte common antigen. Lab Invest. 1984; 51(5):515-23. View

20.

Schlondorff D . The glomerular mesangial cell: an expanding role for a specialized pericyte. FASEB J. 1987; 1(4):272-81. DOI: 10.1096/fasebj.1.4.3308611. View